{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:55:07Z","timestamp":1792234507229,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.amjmed.2018.09.011","type":"journal-article","created":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T19:10:57Z","timestamp":1537384257000},"page":"71-80.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction"],"prefix":"10.1016","volume":"132","author":[{"given":"Essraa","family":"Bayoumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma F.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E.","family":"Palant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-8093","authenticated-orcid":false,"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6424","authenticated-orcid":false,"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2018.09.011_bib0001","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0002","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0003","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.amjmed.2018.09.011_bib0004","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.ahj.2013.03.007","article-title":"Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure","volume":"165","author":"Curtis","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjmed.2013.08.027","article-title":"Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure","volume":"127","author":"Ahmed","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0007","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjmed.2014.11.036","article-title":"Beta-blocker use and 30-day all-cause readmission in Medicare beneficiaries with systolic heart failure","volume":"128","author":"Bhatia","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0008","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2016.05.008","article-title":"Renin-angiotensin system inhibition and lower 30-day all-cause readmission in Medicare beneficiaries with heart failure","volume":"129","author":"Sanam","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0009","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/jama.2012.14795","article-title":"Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction","volume":"308","author":"Hernandez","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0010","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0011","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/j.jacc.2017.08.022","article-title":"Heart rate and outcomes in hospitalized patients with heart failure with preserved ejection fraction","volume":"70","author":"Lam","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0012","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijcard.2011.10.089","article-title":"Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data","volume":"166","author":"Zhang","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0014","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jchf.2012.08.001","article-title":"Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction","volume":"1","author":"Patel","year":"2013","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0015","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity score to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0018","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.amjmed.2012.06.031","article-title":"Renin-angiotensin inhibition in diastolic heart failure and chronic kidney disease","volume":"126","author":"Ahmed","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0019","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1093\/eurheartj\/ehp222","article-title":"A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study","volume":"30","author":"Ahmed","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0020","first-page":"105","article-title":"Sensitivity to hidden bias","volume":"1","author":"Rosenbaum","year":"2002"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0021","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0022","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0023","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","article-title":"The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure","volume":"46","author":"Shah","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0024","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0026","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.amjmed.2018.09.011_bib0027","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.116.002946","article-title":"Characterization of mineralocorticoid receptor antagonist therapy initiation in high-risk patients with heart failure","volume":"10","author":"Cooper","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jcpt.12502","article-title":"Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults","volume":"42","author":"Hanlon","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.amjmed.2018.09.011_bib0029","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.1199","article-title":"Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists","volume":"20","author":"Trevisan","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0030","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0735-1097(02)02694-3","article-title":"Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines","volume":"41","author":"Bozkurt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0031","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0032","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.amjcard.2014.03.062","article-title":"Spironolactone use and higher hospital readmission for Medicare beneficiaries with heart failure, left ventricular ejection fraction <45%, and estimated glomerular filtration rate <45 ml\/min\/1.73 m(2.)","volume":"114","author":"Inampudi","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0033","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ijcard.2016.11.006","article-title":"Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone","volume":"227","author":"Lam","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0034","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1161\/CIRCHEARTFAILURE.112.000115","article-title":"Association of spironolactone use with all-cause mortality in heart failure: a propensity scored cohort study","volume":"6","author":"Lund","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0035","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.amjcard.2013.06.039","article-title":"Effectiveness and safety of spironolactone for systolic heart failure","volume":"112","author":"Lee","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0036","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0037","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","article-title":"Hyperkalemia in heart failure","volume":"68","author":"Sarwar","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0038","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.amjmed.2017.11.011","article-title":"Effect of patiromer on hyperkalemia recurrence in older chronic kidney disease patients taking RAAS inhibitors","volume":"131","author":"Weir","year":"2018","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.amjmed.2018.09.011_bib0039","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ejhf.1182","article-title":"Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry","volume":"20","author":"Savarese","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2018.09.011_bib0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1161\/CIRCOUTCOMES.108.822692","article-title":"Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients","volume":"2","author":"Curtis","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318308787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934318308787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:15:59Z","timestamp":1757582159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934318308787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0002934318308787"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.09.011","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spironolactone and Outcomes in Older Patients with Heart Failure and Reduced Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2018.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}